iiinova — where your digital self keeps evolving

Reposted by Reschke lab

Else Kröner-Fresenius-Stiftung @ekfstiftung.bsky.social · 21/04/2026

🧪 Wie lassen sich Nebenwirkungen von Immuntherapien bei #Hautkrebs besser verstehen und behandeln? Daran forscht PD Dr. Robin Reschke – mit dem Ziel, neue molekulare Angriffspunkte für personalisierte Therapien zu finden. 🎯 ekfs.de/wissenschaft... @drrobinreschke.bsky.social

031

Reposted by Reschke lab

Else Kröner-Fresenius-Stiftung @ekfstiftung.bsky.social · 02/04/2026

Der Deutsche #Krebspreis 2026 geht u.a. an Prof. Felix Sahm, Universitätsklinikum Heidelberg (UKHD) sowie Wissenschaftler am Deutschen Krebsforschungszentrum in der Kategorie „Translationale Forschung“. Wir gratulieren und freuen uns, ihn auf seinem Weg begleitet zu haben. 🎉#EKFS

031

Reposted by Reschke lab

Cancer Core Europe @cancercoreeurope.bsky.social · 25/03/2026

#CCEAM26 marked a special milestone as we celebrated the 10th CCE Annual Meeting, hosted by @ki.se Inspiring science, strong collaboration, and meaningful exchange. Thanks to all organizers, speakers, and attendees! 👉 www.cancercoreeurope.eu/cancer-core-...

182

Reposted by Reschke lab

NCT Heidelberg @nct-heidelberg.bsky.social · 26/03/2026

Beim Cancer Core Europe (CCE) Annual Meeting 2026 am Karolinska Institutet diskutierte die europäische Krebsforschung aktuelle Entwicklungen. Robin Reschke NCT HD erhielt den Early-Career Investigator Award für Arbeiten zur personalisierten Immuntherapie. Mehr: www.nct-heidelberg.de/das-nct/news...

143

Reschke lab @drrobinreschke.bsky.social · 17/02/2026

👉 Interesse am Thema Hautkrebs? Ich freue mich, wenn Sie vorbeikommen und sich mit mir austauschen.

031

Reschke lab @drrobinreschke.bsky.social · 27/01/2026

🧪✨ Can we predict immunotherapy toxicity before treatment starts? Our new study says: yes. Baseline autoantibody profiles predict irAEs & colitis in melanoma—and differ by PD-1 vs CTLA-4 therapy. Toward safer, personalized checkpoint inhibition. Open access 🚀: jitc.bmj.com/content/14/1...

jitc.bmj.com

Autoantibodies as predictors for immune-related adverse events in checkpoint inhibition therapy of metastatic melanoma

Background Immune checkpoint inhibitors have transformed melanoma therapy but frequently cause immune-related adverse events (irAEs), including colitis, that limit treatment. Reliable biomarkers predi...

053

Reschke lab @drrobinreschke.bsky.social · 16/01/2026

Fully funded Post-Doc @Heidelberg 🏰 Interested in cutting edge spatial biology methods 🗺️, computational biology 💻, cancer neuroscience 🧬, microbiome 🦠 and tumor immunology are encouraged to apply for projects 22 and 29. You can directly apply with me🤩 www.health-life-sciences.de/opportunitie...

health-life-sciences.de

HEALTH + LIFE SCIENCE ALLIANCE | Interinstitutional Postdocs

031

Reschke lab @drrobinreschke.bsky.social · 15/01/2026

We invite applications for fully funded inter-institutional postdoctoral positions hosted by DKFZ, EMBL, the University of Heidelberg, and other. Interested candidates are encouraged to apply to projects 22 and 29 and others 😜 www.health-life-sciences.de/opportunitie...

012

Reschke lab @drrobinreschke.bsky.social · 25/12/2025

New podcast alert🚨✨it was nice to take a moment at the end of the year to reflect on the past, both professionally and personally. 🎄If anyone is looking for a new podcast to listen to over the Christmas days, OnCoffee is definitely worth tuning into. youtu.be/vYEbOV4CP7M?...

youtu.be

ONCOFFEE: Robin Reschke – From Side Research to Leading a Lab, with Immunotherapy at the Core

YouTube video by OncoDaily TV

020

Reschke lab @drrobinreschke.bsky.social · 27/11/2025

🌊 HARPOON Conference 2025 — PREDICT Study 🎯 Happy to play a small part in this high-quality DKFZ/DKTK/NCT meeting and to share our latest results from the PREDICT study, which I’m proud to co-lead with Prof. Jessica Hassel. #HARPOON #DKFZ #DKTK #NCT #immunotherapy #cancercoreeurope #melanoma

051

Reschke lab @drrobinreschke.bsky.social · 16/06/2025

✨ Grateful for the opportunity to present some data from my lab today at #EACR2025 in Lisbon! 🧬🔬🇵🇹 It was a pleasure to engage with such an inspiring community of researchers.💡🙌 Thanks to everyone who stopped by, asked questions, and shared ideas — exciting things ahead! 🚀 @helloeacr.bsky.social

0121

Reschke lab @drrobinreschke.bsky.social · 15/06/2025

First time at #EACR — excited to kick off this incredible meeting in beautiful Lisbon! Let the science (and sunshine) begin ☀️🇵🇹 @EACRnews #Lisboa #EACR2025 @helloeacr.bsky.social

0151

Reschke lab @drrobinreschke.bsky.social · 12/06/2025

Feeling very grateful! 🤩🎉 A heartfelt thank you to my amazing MD students for the kind congratulations on my successful habilitation as Privatdozent (Priv.-Doz.) 🐥🎓 😁

050

Reschke lab @drrobinreschke.bsky.social · 10/05/2025

Stellar Keynote lecture from Laura Mackay on TRM cell fate at #SID25 in San Diego @siderm.bsky.social 🤓🤩🎉

010

Reschke lab @drrobinreschke.bsky.social · 09/05/2025

Big thanks to the Society for Investigative Dermatology for an amazing meeting in San Diego so far! Honored to receive an award for our work and the invitation to present 🥳Grateful for the inspiring science, conversations, and community! ☀️#SID2025#DermResearch @siderm.bsky.social

050

Reposted by Reschke lab

NCT Heidelberg @nct-heidelberg.bsky.social · 15/04/2025

Auftakt für TRYTRAC, das europäische Nachwuchsprogramm von Cancer Core Europe (CCE): Junge Wissenschaftler:innen aus sieben Top-Krebszentren – darunter vier Fellows aus Heidelberg – trafen sich am Karolinska Institutet in Stockholm. 🔗 www.nct-heidelberg.de/das-nct/news...

163

Reschke lab @drrobinreschke.bsky.social · 11/04/2025

🚨New research highlight: study on managing immunotherapy side effects without weakening anti-tumor power! ECP reduces harmful immune activity via neutrophils/T cells & promotes M2 macrophages via adiponectin. Promising results from Zeiser et al. 🔬 🧪 🧫 Full summary: www.nature.com/articles/s41...

nature.com

Adiponectin to the rescue: extracorporeal photopheresis for managing immune checkpoint inhibitor-induced toxicities - Signal Transduction and Targeted Therapy

Signal Transduction and Targeted Therapy - Adiponectin to the rescue: extracorporeal photopheresis for managing immune checkpoint inhibitor-induced toxicities

042

Reposted by Reschke lab

Cancer Core Europe @cancercoreeurope.bsky.social · 28/01/2025

📖 “Targeting molecular pathways to control immune checkpoint inhibitor toxicities” co-authored by @drrobinreschke.bsky.social from @nct-heidelberg.bsky.social @dkfz.bsky.social 🔗 www.cell.com/trends/immunology/full…

1163

Reposted by Reschke lab

Health + Life Science Alliance Heidelberg Mannheim @hlsalliance.bsky.social · 15/01/2025

Heidelberg is placing first when it comes to #startup founders per capita in #Germany. With 13.5 new startups per 100.000 inhabitants in 2024, Heidelberg is outperforming startup hotspots such as #Berlin and #Munich. The full report is here: startupverband.de/fileadmin/st...

0113

Reschke lab @drrobinreschke.bsky.social · 15/01/2025

Now featured and OPEN ACCESS 💫👏🏻🚀

031

Reposted by Reschke lab

Waggoner Lab @labwaggoner.bsky.social · 29/12/2024

Review: Targeting molecular pathways to control immune checkpoint inhibitor toxicities www.cell.com/trends/immun...

1102

Reschke lab @drrobinreschke.bsky.social · 28/12/2024

Hot off the press 🔥 Very proud of this collaboration! 💫 @Harvard @JohnsHopkins @UChicago @UniHeidelberg Interested in immunotherapy-induced toxicity? 🤓 This is a must-read 🤩 #immunology #science #cancer #research @nct-heidelberg.bsky.social @dkfz.bsky.social www.cell.com/trends/immun...

13111

Reschke lab @drrobinreschke.bsky.social · 24/12/2024

⚠️ Anti-PD1 therapy could serve as an effective systemic treatment for patients with basal cell nevus syndrome who are resistant to hedgehog inhibitors, leveraging the immune system to address new occurrences of basal cell carcinoma 💡🧠🔬. 🔗 Read the full study here: jamanetwork.com/journals/jam...

jamanetwork.com

Use of Anti-PD1 Blockade After Hedgehog Inhibitors or as First-Line Therapy for Gorlin Syndrome

This case series examines treatment with anti–programmed cell death 1 (PD1) immunotherapy for patients with basal cell nevus syndrome.

053

Reschke lab @drrobinreschke.bsky.social · 21/12/2024

🌟 Our latest article gives an update about prognostic biomarkers in evolving melanoma immunotherapy: From PD-L1 to gut microbiota and beyond 🧬💊 Enjoy the weekend read 📖 : link.springer.com/article/10.1... 📌 #Melanoma #Immunotherapy #ScienceForAll #ResearchMatters #Innovation #dermatology ---

link.springer.com

0102

Reschke lab @drrobinreschke.bsky.social · 20/12/2024

What an amazing Secret Santa exchange on the lab floor! 🤩🎁🎄 So much laughter, surprises, and holiday cheer – can't wait to do it again next year! ✨🎅 @nct-heidelberg.bsky.social

050

Reschke lab @drrobinreschke.bsky.social · 14/12/2024

Dermatology: A group for researchers, clinicians, patient advocates, journals, and institutions passionate about dermatology research and advancing skin health! 🩺✨ #Dermatology #SkinHealth #ScienceCommunity Leave a comment, if you want to join the starter pack 😊 go.bsky.app/7BoDoFw

170

Reschke lab @drrobinreschke.bsky.social · 09/12/2024

Favorite protein: Dickkopf-related protein 1 Dickkopf is German for bullhead or bullethead 😂

090

Reschke lab @drrobinreschke.bsky.social · 08/12/2024

Everything #spatialomics - A hub for researchers, clinicians, companies, journals, and institutions exploring spatial omics technologies. Leave a comment, if you’d like to join 🧬🙂 #SpatialOmics #Visium #Xenium #MERSCOPE #MultiplexIF #MIBI #OmicsResearch #Biotech #Innovation go.bsky.app/zcDshW

893

Reschke lab @drrobinreschke.bsky.social · 08/12/2024

Skin Cancer Research: Melanoma and beyond. A space for patient advocates, scientists, physicians, institutions, and journals dedicated to advancing skin cancer research. 🧫🧑‍🔬🔬 Leave a comment and let me know if you'd like to join! #Cure #SkinCancer #Research go.bsky.app/2wqZKrA

10296